Treatment

AZD6234 clinical trials

Active studies that list AZD6234 as an intervention or treatment.

6active studies

2recruiting now

11countries represented

218largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

Obesity or OverweightCondition

AZD6234, PlaceboTreatment

Argentina, Australia212 locations

AstraZenecaSponsor

Updated 2026-08-25 · NCT07784725See eligibility →

Recruiting nowPhase 1

A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity

Healthy ParticipantsCondition

AZD6234, Ethinyl estradiol/Levonorgestrel (EE/LEVO)Treatment

United States2 locations

AstraZenecaSponsor

Updated 2026-08-18 · NCT07013643See eligibility →

Opening soonPhase 3

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

Obesity or Overweight, Diabetes Mellitus, Type 2Condition

AZD6234, PlaceboTreatment

Argentina, Australia218 locations

AstraZenecaSponsor

Updated 2026-08-25 · NCT07784270See eligibility →

Opening soonPhase 3

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

Obesity or Overweight, Weight-Related ComorbidityCondition

AZD6234, PlaceboTreatment

Argentina, Brazil88 locations

AstraZenecaSponsor

Updated 2026-08-20 · NCT07776509See eligibility →

Active, not recruitingPhase 2

This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight

Obesity/OverweightCondition

AZD6234, PlaceboTreatment

China3 locations

AstraZenecaSponsor

Updated 2026-07-02 · NCT07017179See eligibility →

Active, not recruitingPhase 2

Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist

Endocrinology, Diabetes, Type IICondition

AZD6234, Placebo to matchTreatment

United States18 locations

AstraZenecaSponsor

Updated 2026-03-03 · NCT06851858See eligibility →

Related treatments

Placebo421 Tirzepatide119 Semaglutide91 Control30 Exercise27 Orforglipron21

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.